Arcus Biosciences, Inc.

Arcus Biosciences is a late clinical-stage biopharmaceutical company headquartered in Hayward, California, focused on the discovery, development, and commercialization of differentiated molecules and combination therapies. Founded in 2015, the company's core mission is to combine expertise in science and medicine to pursue cures for cancer, leveraging well-characterized biologic pathways to create innovative treatments.

The company's pipeline primarily targets oncology, with investigational products including Domvanalimab (an anti-TIGIT antibody), Quemliclustat (a CD73 inhibitor), Casdatifan (a HIF-2α inhibitor), and Zimberelimab (an anti-PD-1 antibody). Arcus Biosciences develops both small molecules and biologics, with a research platform centered on modulating tumor microenvironments and immune checkpoints to enhance anti-tumor immune responses.

Arcus Biosciences is led by co-founder and CEO Terry Rosen, PhD. The company recently announced a clinical trial collaboration with Bristol Myers Squibb in June 2026 to evaluate Casdatifan in combination with pumitamig for kidney cancer, highlighting a strategic focus on this HIF-2α inhibitor. This follows a strategic realignment and a partial wind-down of a previous collaboration with Gilead Sciences, though Gilead maintains a significant equity stake and a 10-year co-development and co-commercialization partnership, providing substantial financial backing.